Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(18):1261-1263; doi:10.1093/jnci/djj387
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Van Poznak, C. H.
Right arrow Articles by Hayes, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Poznak, C. H.
Right arrow Articles by Hayes, D. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

Aromatase Inhibitors for the Treatment of Breast Cancer: Is Tamoxifen of Historical Interest Only?

Catherine H. Van Poznak, Daniel F. Hayes

Affiliation of authors: Breast Oncology Program, University of Michigan Comprehensive Cancer Center, and the Department of Internal Medicine, University of Michigan Health and Hospital System, Ann Arbor, MI

Correspondence to: Daniel F. Hayes, MD, 6312 Cancer Center Geriatrics Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109 (e-mail: hayesdf@umich.edu).

The first 150 words of the full text of this article appear below.

Breast cancer is the second most common cause of death from malignancy in American women (1). Although it is almost uniformly fatal, metastatic breast cancer is very treatable, and many patients will live for long periods of time with good quality of life (2). In this regard, nearly 100 000 patients are living with metastatic breast cancer in the United States (3).

There is reason to be optimistic that the life expectancy of patients with metastatic breast cancer will be extended further as novel therapies targeting growth pathways, cell signaling, and tumor microenvironment are developed. Among these therapies, the oldest and most effective are those that target the estrogen receptor pathway. Although the importance of endocrine control of breast cancer was recognized by Beatson 110 years ago (4), the field is still exploring means of optimizing endocrine therapy. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?